Quratis Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 42

Employees

  • Stock Symbol
  • 348080

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.65
  • (As of Friday Closing)

Quratis General Information

Description

Quratis Inc operates as a developer of vaccines and therapies designed to treat tuberculosis. The company develops youth and adults tuberculosis vaccines, messenger ribonucleic acids, and other related immune-related vaccines.

Contact Information

Website
www.quratis.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Osong bioplant. 625-19, Yeonje-ri, Osong-eup
  • Heungdeok
  • Cheongju, Chungcheongbuk
  • South Korea
+82
Primary Industry
Drug Discovery
Stock Exchange
KRX
Corporate Office
  • Osong bioplant. 625-19, Yeonje-ri, Osong-eup
  • Heungdeok
  • Cheongju, Chungcheongbuk
  • South Korea
+82

Quratis Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Quratis Stock Performance

As of 13-Nov-2026, Quratis’s stock price is $2.65. Its current market cap is $33.9M with 12.8M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.65 $2.65 $1.21 - $9.06 $33.9M 12.8M 130K -$1.78

Quratis Financials Summary

As of 30-Jun-2026, Quratis has a trailing 12-month revenue of $755K.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 19,961 70,324 38,211 84,257
Revenue 755 1,726 274 788
EBITDA (12,218) (15,611) (14,573) (7,479)
Net Income (16,466) (20,850) (19,251) (12,995)
Total Assets 37,650 38,007 31,668 52,148
Total Debt 6,173 6,625 11,858 16,674
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Quratis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Quratis‘s full profile, request access.

Request a free trial

Quratis Patents

Quratis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021187932-A1 Vaccine composition for preventing hand, foot, and mouth disease, comprising gla-se Inactive 20-Mar-2020
WO-2021107548-A1 Biomarker for diagnosis of infections or infectious diseases caused by nontuberculous mycobacteria Inactive 25-Nov-2019
WO-2021107551-A1 Biomarker for distinguishing infectious diseases caused by nontuberculous mycobacteria Inactive 25-Nov-2019
WO-2021107549-A1 Biomarker for predicting spontaneous negative conversion of bacteria after infection with nontuberculous mycobacteria Inactive 25-Nov-2019
WO-2021107598-A1 Biomarker for predicting treatment responsiveness after infection by nontuberculous mycobacteria Inactive 25-Nov-2019 G01N33/68
To view Quratis’s complete patent history, request access »

Quratis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Quratis Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Quratis‘s full profile, request access.

Request a free trial

Quratis Investments (1)

Quratis’s most recent deal was a Early Stage VC with CellnLife. The deal was made on 31-May-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CellnLife 31-May-2021 Early Stage VC Therapeutic Devices
To view Quratis’s complete investments history, request access »

Quratis ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Quratis’s complete esg history, request access »

Quratis Exits (1)

Quratis’s most recent exit was on 31-May-2021 from CellnLife. The exit was categorized as with 3 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
CellnLife 31-May-2021 Completed
  • 3 buyers
To view Quratis’s complete exits history, request access »

Quratis FAQs

  • When was Quratis founded?

    Quratis was founded in 2016.

  • Where is Quratis headquartered?

    Quratis is headquartered in Cheongju, South Korea.

  • What is the size of Quratis?

    Quratis has 42 total employees.

  • What industry is Quratis in?

    Quratis’s primary industry is Drug Discovery.

  • Is Quratis a private or public company?

    Quratis is a Public company.

  • What is Quratis’s stock symbol?

    The ticker symbol for Quratis is 348080.

  • What is the current stock price of Quratis?

    As of 13-Nov-2026 the stock price of Quratis is $2.65.

  • What is the current market cap of Quratis?

    The current market capitalization of Quratis is $33.9M.

  • What is Quratis’s current revenue?

    The trailing twelve month revenue for Quratis is $755K.

  • What is Quratis’s annual earnings per share (EPS)?

    Quratis’s EPS for 12 months was -$1.78.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process